InflaRx Announces Vilobelimab Phase III Results in Critically Ill COVID-19 Patients Published in The Lancet Respiratory Medicine
September 08, 2022 07:30 ET
|
InflaRx N.V.
The Lancet Respiratory Medicine, a peer-reviewed journal, published the results of the PANAMO trial, one of the largest, global, 1:1 randomized, placebo-controlled Phase III studies conducted in...
Emergent BioSolutions Announces Publication of CHIKV VLP Phase 2 Safety and Immunogenicity Data in The Lancet Infectious Diseases
June 21, 2022 06:30 ET
|
Emergent BioSolutions
GAITHERSBURG, Md., June 21, 2022 (GLOBE NEWSWIRE) -- Emergent BioSolutions Inc. (NYSE:EBS) announced today that two-year persistence data from its phase 2 clinical study evaluating the safety and...
Worldwide Capillary and Venous Blood Sampling Devices Industry to 2030 - Featuring Terumo, Thermo Fisher Scientific & Owen Mumford Among Others
November 05, 2020 05:58 ET
|
Research and Markets
Dublin, Nov. 05, 2020 (GLOBE NEWSWIRE) -- The "Capillary and Venous Blood Sampling Devices Market - Global Industry Analysis, Size, Share, Growth, Trends, and Forecast, 2020 - 2030" report has been...
United States Blood Sugar Lancets Market Growth, Demand, Trends, Opportunity, Forecasts 2015-2020 & 2027
September 25, 2020 08:49 ET
|
Research and Markets
Dublin, Sept. 25, 2020 (GLOBE NEWSWIRE) -- The "U.S. Blood Sugar Lancets Market - Growth, Demand, Trends, Opportunity, Forecasts (2020 - 2027)" report has been added to ResearchAndMarkets.com's...
Lancet Market Size Is Estimated To Grow at a CAGR of 10.50% By 2024, Predicts Market Research Future
July 30, 2019 09:14 ET
|
Market Research Future
Pune, India, July 30, 2019 (GLOBE NEWSWIRE) -- Market Overview As per a report made available by Market Research Future, the Lancet Market is expected to expand at a CAGR of 10.50% in the upcoming...
Nanobiotix annonce la publication dans le Lancet Oncology des données de phase III dans le Sarcome des Tissus Mous pour NBTXR3 son produit premier d'une nouvelle classe
July 09, 2019 14:45 ET
|
Nanobiotix S.A.
NANOBIOTIX ANNONCE LA PUBLICATION DANS LE LANCET ONCOLOGY DES DONNÉES DE PHASE III DANS LE SARCOME DES TISSUS MOUS POUR NBTXR3 SON PRODUIT PREMIER D’UNE NOUVELLE CLASSE Les données...
Nanobiotix announces publication of phase III Soft Tissue Sarcoma data for first-in-class NBTXR3 in the Lancet Oncology
July 09, 2019 14:45 ET
|
Nanobiotix S.A.
NANOBIOTIX ANNOUNCES PUBLICATION OF PHASE III SOFT TISSUE SARCOMA DATA FOR FIRST-IN-CLASS NBTXR3 IN THE LANCET ONCOLOGY Previously reported data from the registration study (Act.In.Sarc)...
Phase 2 CoDIFy Trial Results Published in Lancet Infectious Diseases With Data Showing Summit’s Ridinilazole Achieved Statistical Superiority over Vancomycin in the Treatment of C. Difficile Infection
April 28, 2017 18:30 ET
|
Summit Therapeutics PLC
OXFORD, United Kingdom, April 28, 2017 (GLOBE NEWSWIRE) -- Summit Therapeutics plc (AIM:SUMM) (NASDAQ:SMMT), the drug discovery and development company advancing therapies for Duchenne muscular...
Bionor Pharma's Phase II Vacc-4x Data Published in the Lancet Infectious Diseases
February 11, 2014 09:27 ET
|
Bionor Pharma
OSLO, NORWAY--(Marketwired - Feb 11, 2014) - Bionor Pharma ASA (OSE: BIONOR) announces that the results from the randomized, multicenter, double-blinded, placebo-controlled Phase II trial with 135...